Decoding In Vivo CAR-T: From Market Insights to Industrial Practice

Ph.D. in Chemistry from Peking University, with years of research experience in structural biology and autophagy. The research focus is on protein degraders, antibody drugs, and mRNA vaccines.ADC Drugs, cell and gene therapy, small nucleic acid drugs, AI pharmaceuticals, and other fields, with insights into the current status and development of various segments in the innovative drug industry.In-depth research, long-term observation of entrepreneurs in the healthcare and health industry, and profound understanding of the pharmaceutical equity investment market and industrial policies.

Dr. Zeng Xian graduated from the National University of Singapore with a Ph.D. in Pharmacy and completed his postdoctoral research. His academic expertise lies in nucleic acid drug design and biotechnology, laying a solid foundation for both scientific research and entrepreneurship. He served as an associate researcher at the School of Pharmacy, Fudan University, focusing on AI-driven mRNA drug development, and accumulated extensive experience in intelligent design of nucleic acid drugs and gene delivery, publishing nearly 70 papers in international authoritative journals. In 2023, he co-founded Byterna Therapeutics, which focuses on the development of in vivo CAR-T therapies using circular mRNA. Leading his team to overcome challenges such as circular mRNA synthesis, he has built a globally leading development platform, advancing therapies from the lab to clinical trials and addressing issues of high costs and poor accessibility associated with traditional treatments. He is also active in international academic conferences and industry forums, sharing technological breakthroughs and providing insights for industry integration, guiding Byterna Therapeutics to continuously achieve breakthroughs in the cell therapy field.

Bachelor of Science from the Biology Department of Wuhan University, Ph.D. from the Biology Department of Ludwig Maximilian University of Munich, Germany, and Postdoctoral Fellow from the School of Medicine at Johns Hopkins University, USA. Dr. Lei Xiao has been engaged in stem cell research and...Transgenic AnimalsResearch, a series of achievements and progress have been made in the field of stem cell and iPS research, successively.Published more than ten SCI research papers as corresponding author in journals such as Cell Stem Cell, JBC, Cell Research, JMCB, and two invited reviews, including the first report internationally on the establishment of rat models.iPS CellsThe team's work, with related research achievements published in the journal Cell Stem Cell, has provided the first fundamental proof internationally that iPS technology can establish pluripotent stem cell lines for species that have historically been difficult to derive ES cell lines from. Dr. Xiao Lei has served as a Research Group Leader, Research Fellow, and Ph.D. supervisor at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Deputy Dean of the Institute of Translational Medicine, Zhejiang University; Professor and Ph.D. supervisor at the School of Medicine, Zhejiang University, and Director of the Zhejiang University Stem Cell and Development Research Center.

Graduated from the Department of Sociology at Peking University, a specially invited lecturer at the School of Lifelong Education, Shanghai Jiao Tong University, focusing on investment and research in cutting-edge technology fields such as biomedicine, and is an expert in corporate industrial incubation.CICA pioneer in models and the concept of AI RaaS (Result as a Service), with years of experience in raising, managing, investing, and exiting both mother funds and direct investment funds. Joined Shengjing Jicheng in 2016, which manages over 13 billion yuan in mother funds and direct investment funds. The firm has invested in more than 60 top-tier fund managers in China and the US, and has seen 268 portfolio companies successfully go public, achieving notable success in cross-cycle exits. Ranked 15th on the LP Think Tank's 2021 list of Chinese LPs with significant real cash exits (with the top position held by the Ministry of Finance of the People's Republic of China).

Ph.D. in Biomedical Engineering from the School of Medicine, Tsinghua University; Postdoctoral fellow at the Technical Institute of Physics and Chemistry, Chinese Academy of Sciences. With nearly a decade of professional equity investment experience, having previously been responsible for equity and strategic investments in a listed company. Currently at Daoyuan Capital, primarily focusing on innovative drugs and biotechnology fields, including small molecules, antibodies, cell therapy, and gene therapy, among others.

Master's and Ph.D. graduated from Fudan University majoring in drug delivery, and bachelor’s degree from Shandong University majoring in pharmacy. Main investment directionCovering tumor immunology, ADC, and autoimmune diseases,CGTInnovative RNA therapy and other fields, with nearly 10 years of experience in startup investment, pharmaceutical enterprise BD/JV cooperation, and early-stage innovative drug incubation. Before joining Gortica, Dr. Kang Ting was involved in innovative drug investment at Fosun Pharma and served as a core founding member of Fosun Health Capital's new drug innovation fund. She also served as Investment Director at Cowin Venture Capital, where she was responsible for the investment management of multiple internationally leading projects. Key investment cases: Biotherapy Biotech, Boao Mingmatch, Fure Bio, Aokoda Pharmaceuticals, BridGene, Cambridge Innovation Capital, etc.